Spots Global Cancer Trial Database for Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Official Title: A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Study ID: NCT02760498
Interventions
Study Description
Brief Summary: Groups 1 to 4 To estimate the clinical benefit of cemiplimab monotherapy for patients with: metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), or unresectable locally advanced CSCC Group 6 To provide additional efficacy and safety data for cemiplimab monotherapy in patients with advanced CSCC (metastatic \[nodal or distant\] or locally advanced treated with cemiplimab
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Arizona Cancer Center, Phoenix, Arizona, United States
Mayo Clinic, Phoenix, Arizona, United States
City of Hope Hospital, Duarte, California, United States
University of California, Los Angeles, Los Angeles, California, United States
Stanford University, Redwood City, California, United States
University of California, San Diego, San Diego, California, United States
University of Colorado, Denver, Aurora, Colorado, United States
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Northwestern University, Chicago, Illinois, United States
Norton Cancer Institute, Louisville, Kentucky, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
St. Louis University, Saint Louis, Missouri, United States
Washington University in St. Louis, Saint Louis, Missouri, United States
Nebraska Methodist Hospital, Omaha, Nebraska, United States
New York University, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of Rochester Medical Center, Rochester, New York, United States
Cleveland Clinic, Cleveland, Ohio, United States
St. Luke's Hematology Oncology Specialists, Easton, Pennsylvania, United States
Penn State Hershey Medical Center, Hershey, Pennsylvania, United States
Dermatology and Laser Center of Charleston, Charleston, South Carolina, United States
MD Anderson Cancer Center, Houston, Texas, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
The Canberra Hospital, Garran, Australian Capital Territory, Australia
Gosford Hospital, Gosford, New South Wales, Australia
Royal North Shore Hospital, St Leonards, New South Wales, Australia
Calvary Mater Newcastle, Waratah, New South Wales, Australia
Royal Brisbane & Women's Hospital, Herston, Queensland, Australia
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Adelaide Cancer Centre, Kurralta Park, South Australia, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Border Medical Oncology, Wodonga, Victoria, Australia
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
Liga Paranaense de Combate Ao Cancer - Hospital Erasto Gaertner, Curitiba, , Brazil
Fundação São Francisco Xavier-Hospital Márcio Cunha, Ipatinga, , Brazil
Animi, Lages, , Brazil
Instituto do Cancer do Estado de São Paulo ICESP, Sao Paulo, , Brazil
Fundação Antônio Prudente - AC Camargo Câncer Center, São Paulo, , Brazil
Hôpital Claude Huriez, Lille, Nord, France
Hopital Avicenne, Bobigny, , France
Hôpital Saint-André, Bordeaux, , France
CHU Dijon Bourgogne, Dijon, , France
CHRU Grenoble, Grenoble, , France
Hopitaux de La Timone, Marseille, , France
Centre Hospitalier Universitaire de Nantes, Nantes, , France
Hopital Cochin, Paris, , France
Hôpital Saint Louis, Paris, , France
Centre Hospitalier Lyon Sud, Pierre Bénite, , France
Institut Gustave Roussy, Villejuif, , France
Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany
LMU Klinikum der Universität München, Munich, Bayern, Germany
Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany
Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany
Universitatsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany
Charitè Campus Mitte, Berlin, , Germany
SRH Wald-Klinikum Gera, Gera, , Germany
Andreas Sygros Hosptial-University of Athen, Athens, , Greece
Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy
Istituto Oncologico Veneto - I.R.C.C.S., Padova, Veneto, Italy
ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia, Brescia, , Italy
Ospedale San Salvatore, L'Aquila, , Italy
Istituto Europeo Di Oncologia, Milan, , Italy
Fondazione Policlinico Universitario A Gemelli, Roma, , Italy
ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barelona, Spain
Hospital Clinic de Barcelona, Barcelona, Cataluna, Spain
Hospital Universitario Vall d'Hebron, Barcelona, , Spain
Hospital Universitario Germans Trias i Pujol, Barcelona, , Spain
C.H. Regional Reina Sofia - PPDS, Cordoba, , Spain
Hospital Universitario Ramon y Cajal, Madrid, , Spain
Hospital Universitario Fundacion Jimenez Diaz, Madrid, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Hospital Universitario Marques de Valdecilla, Santander, , Spain
Fundacion Instituto Valenciano de Oncología, Valencia, , Spain
Contact Details
Name: Clinical Trial Management
Affiliation: Regeneron Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
